Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770718 | 0.93 | PRMT5 (0.41) | PRMT5WDR77ITGB3ITGA2BCHRM4 | |
| SCHEMBL15378491 | 0.87 | EPHX2 (0.38) | PRMT5WDR77CHRM4CYP2C19EPHX2 | |
| SCHEMBL770575 | 0.82 | EPHX2 (0.40) | PRMT5WDR77HRH3EPHX2NAMPT | |
| SCHEMBL770696 | 0.82 | MEN1 (0.38) | ITGB3ITGA2BCYP2C9EPHX2ALDH1A1 | |
| SCHEMBL770666 | 0.80 | RBP4 (0.44) | ITGB3ITGA2BALDH1A1 | |
| SCHEMBL770381 | 0.80 | ITGB3 (0.41) | ITGB3ITGA2BEPHX2ALDH1A1 | |
| SCHEMBL770768 | 0.80 | ITGB3 (0.41) | ITGB3ITGA2BEPHX2ALDH1A1 | |
| SCHEMBL771656 | 0.78 | MAPK1 (0.36) | HRH3ALDH1A1NAMPT | |
| SCHEMBL2938032 | 0.78 | RAB9A (0.35) | ALDH1A1 | |
| SCHEMBL2824310 | 0.78 | RAB9A (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | PRMT5 2098/4885WDR77 1476/4885ITGB3 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.